Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Please provide your email address to receive an email when new articles are posted on . This study compared risankizumab with other biologics in both biologic-naïve and biologic-experienced patients.

Please provide your email address to receive an email when new articles are posted on . After 1 year of continuous risankizumab use, 55.4% and 55.8% of patients achieved IGA 0 and PASI 100, ...

Psoriasis Area and Severity Index scores indicated that patients with moderate-to-severe psoriasis had improved skin clearance when treated with risankizumab compared with secukinumab treatment.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Risankizumab ...

Selective inhibition of interleukin (IL)-23 with the investigational drug risankizumab may be more effective in treating psoriasis than ustekinumab, a less specific drug, a phase 2 study suggests.

Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, ...

AbbVie has posted an analysis of patient-reported outcomes from phase 3 trials of risankizumab. The analysis builds out the evidence in support of the IL-23 antibody ahead of anticipated approvals ...

Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in patients ...

The BLA is supported by data from the global risankizumab Phase 3 psoriasis program evaluating more than 2,000 patients. AbbVie announced the submission of a Biologics License Application (BLA) to the ...

- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European ...